We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study.
- Authors
Marfella, Raffaele; D'Onofrio, Nunzia; Sardu, Celestino; Scisciola, Lucia; Maggi, Paolo; Coppola, Nicola; Romano, Ciro; Messina, Vincenzo; Turriziani, Fabrizio; Siniscalchi, Mario; Maniscalco, Mauro; Boccalatte, Marco; Napolitano, Giovanni; Salemme, Luigi; Marfella, Ludovica Vittoria; Basile, Eugenio; Montemurro, Maria Vittoria; Papa, Carmela; Frascaria, Francesco; Papa, Antonio
- Abstract
By contrast, potent neutralization responses were observed in all the participants 21 days after the second dose of the vaccine; on Day 21 after the second vaccine dose, T2D patients with HbA1c >7% showed significantly reduced virus-neutralizing antibody capacity than normoglycaemic subjects and T2D patients with good glycaemic control ( I P i < 0.05). Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study According to Standards of Medical Care in Diabetes 2021,11 HbA1c levels were evaluated after 75 ± 4 days in patients without diabetes, 73 ± 5 days in T2D patients with good glycaemic control, and 73 ± 6 days in T2D patients with poor glycaemic control (Supplementary Table). At the final follow-up evaluation, virus-neutralizing antibodies and antigen-specific CD4 SP + sp T-cell responses remained higher in participants without diabetes and T2D patients with good glycaemic control than in T2D patients with poor glycaemic control (Figure 2).
- Subjects
GLYCEMIC control; COVID-19; COVID-19 vaccines; TYPE 2 diabetes; MONONUCLEAR leukocytes; INTERLEUKIN-9; REGULATORY T cells; LYMPHOCYTE count
- Publication
Diabetes, Obesity & Metabolism, 2022, Vol 24, Issue 1, p160
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.14547